Acadia raises 2026 total revenue guidance to $1.24-$1.30 bln, up from $1.22-$1.28 bln
Company lifts 2026 DAYBUE sales guidance to $480-$510 mln, up from $460-$490 mln
Acadia expects topline Phase 2 remlifanserin results for Alzheimer's psychosis in Sep-Oct 2026
Overview
Neurology drugmaker's Q2 revenue rose 16% yr/yr, driven by DAYBUE and NUPLAZID sales
Q2 net income and EPS increased from prior year
Company raised full-year 2026 revenue outlook, citing higher DAYBUE guidance
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Acadia Pharmaceuticals Inc is $35.00, about 36.7% above its August 3 closing price of $25.61
The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 36 three months ago
Result drivers and key details
- Co said continued patient demand and robust uptake of DAYBUE STIX drove sales growth
ACAD•
